Skip to content
TriangleGet started
← Full study record

NCT00075946 · BASELINE

Baseline characteristics

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma · Source last updated 2024-02-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      143
    2. group Id
      BG001
      value
      146
    3. group Id
      BG002
      value
      23
    4. group Id
      BG003
      value
      29
    5. group Id
      BG004
      value
      341
    units
    Participants
groups
  1. description
    Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG000
    title
    Rituximab Retreatment: Follicular Patients
  2. description
    Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG001
    title
    Rituximab Scheduled: Follicular Patients
  3. description
    Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG002
    title
    Rituximab Retreatment: Non-Follicular Patients
  4. description
    Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG003
    title
    Rituximab Scheduled: Non-Follicular Patients
  5. description
    Total of all reporting groups
    id
    BG004
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          25
          upper Limit
          86
          value
          59
        2. group Id
          BG001
          lower Limit
          25
          upper Limit
          86
          value
          58
        3. group Id
          BG002
          lower Limit
          47
          upper Limit
          86
          value
          61
        4. group Id
          BG003
          lower Limit
          38
          upper Limit
          85
          value
          65
        5. group Id
          BG004
          lower Limit
          25
          upper Limit
          86
          value
          60
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          76
        2. group Id
          BG001
          value
          80
        3. group Id
          BG002
          value
          16
        4. group Id
          BG003
          value
          14
        5. group Id
          BG004
          value
          186
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          67
        2. group Id
          BG001
          value
          66
        3. group Id
          BG002
          value
          7
        4. group Id
          BG003
          value
          15
        5. group Id
          BG004
          value
          155
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
As the primary analysis only includes randomized patients, the baseline characteristics were provided among patients who were correctly randomized to one of the two arms for maintenance therapy.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      143
    2. group Id
      BG001
      value
      146
    3. group Id
      BG002
      value
      23
    4. group Id
      BG003
      value
      29
    5. group Id
      BG004
      value
      341
    units
    Participants
groups
  1. description
    Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG000
    title
    Rituximab Retreatment: Follicular Patients
  2. description
    Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG001
    title
    Rituximab Scheduled: Follicular Patients
  3. description
    Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG002
    title
    Rituximab Retreatment: Non-Follicular Patients
  4. description
    Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.
    id
    BG003
    title
    Rituximab Scheduled: Non-Follicular Patients
  5. description
    Total of all reporting groups
    id
    BG004
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          25
          upper Limit
          86
          value
          59
        2. group Id
          BG001
          lower Limit
          25
          upper Limit
          86
          value
          58
        3. group Id
          BG002
          lower Limit
          47
          upper Limit
          86
          value
          61
        4. group Id
          BG003
          lower Limit
          38
          upper Limit
          85
          value
          65
        5. group Id
          BG004
          lower Limit
          25
          upper Limit
          86
          value
          60
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          76
        2. group Id
          BG001
          value
          80
        3. group Id
          BG002
          value
          16
        4. group Id
          BG003
          value
          14
        5. group Id
          BG004
          value
          186
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          67
        2. group Id
          BG001
          value
          66
        3. group Id
          BG002
          value
          7
        4. group Id
          BG003
          value
          15
        5. group Id
          BG004
          value
          155
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
As the primary analysis only includes randomized patients, the baseline characteristics were provided among patients who were correctly randomized to one of the two arms for maintenance therapy.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice